全文获取类型
收费全文 | 45233篇 |
免费 | 3105篇 |
国内免费 | 118篇 |
专业分类
耳鼻咽喉 | 555篇 |
儿科学 | 1318篇 |
妇产科学 | 840篇 |
基础医学 | 5675篇 |
口腔科学 | 606篇 |
临床医学 | 5381篇 |
内科学 | 9569篇 |
皮肤病学 | 379篇 |
神经病学 | 4499篇 |
特种医学 | 1577篇 |
外科学 | 6440篇 |
综合类 | 574篇 |
一般理论 | 97篇 |
预防医学 | 4409篇 |
眼科学 | 602篇 |
药学 | 2850篇 |
1篇 | |
中国医学 | 44篇 |
肿瘤学 | 3040篇 |
出版年
2023年 | 286篇 |
2022年 | 409篇 |
2021年 | 1097篇 |
2020年 | 658篇 |
2019年 | 1104篇 |
2018年 | 1306篇 |
2017年 | 867篇 |
2016年 | 1043篇 |
2015年 | 1157篇 |
2014年 | 1649篇 |
2013年 | 2131篇 |
2012年 | 3479篇 |
2011年 | 3547篇 |
2010年 | 1928篇 |
2009年 | 1620篇 |
2008年 | 3064篇 |
2007年 | 3214篇 |
2006年 | 3055篇 |
2005年 | 3004篇 |
2004年 | 2751篇 |
2003年 | 2578篇 |
2002年 | 2445篇 |
2001年 | 434篇 |
2000年 | 307篇 |
1999年 | 412篇 |
1998年 | 475篇 |
1997年 | 366篇 |
1996年 | 311篇 |
1995年 | 314篇 |
1994年 | 267篇 |
1993年 | 248篇 |
1992年 | 239篇 |
1991年 | 228篇 |
1990年 | 192篇 |
1989年 | 164篇 |
1988年 | 150篇 |
1987年 | 156篇 |
1986年 | 151篇 |
1985年 | 143篇 |
1984年 | 167篇 |
1983年 | 141篇 |
1982年 | 157篇 |
1981年 | 149篇 |
1980年 | 104篇 |
1979年 | 82篇 |
1978年 | 77篇 |
1977年 | 60篇 |
1976年 | 45篇 |
1974年 | 48篇 |
1971年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
2.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
3.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
4.
5.
6.
Andrea Stracciolini Jennifer Luz Gregory Walker Nicholas M. Edwards Avery D. Faigenbaum Gregory D. Myer 《The Physician and sportsmedicine》2020,48(2):199-207
ABSTRACT
Objective
To investigate primary care physician clinical practice patterns, barriers, and education surrounding pediatric physical activity (PA), and to compare practice patterns by discipline. 相似文献7.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
8.
9.
Gregory S. Orgel Robert A. Weston Christopher Ziebell Lawrence H. Brown 《The American journal of emergency medicine》2019,37(9):1729-1733
ObjectiveTo evaluate changes in insurance status among emergency department (ED) patients presenting in the two years immediately before and after full implementation of the Affordable Care Act (ACA).MethodsWe evaluated National Hospital Ambulatory Medical Care Survey (NHAMCS) Emergency Department public use data for 2012–2015, categorizing patients as having any insurance (private; Medicare; Medicaid; workers' compensation) or no insurance. We compared the pre- and post-ACA frequency of insurance coverage—overall and within the older (≥65), working-age (18–64) and pediatric (<18) subpopulations—using unadjusted odds ratios with 95% confidence intervals. We also conducted a difference-in-differences analysis comparing the change in insurance coverage among working-age patients with that observed for older Medicare-eligible patients, while controlling for sex, race and underlying temporal trends.ResultsOverall, the proportion of ED patients with any insurance did not significantly change from 2012 to 2013 to 2014–2015 (74.2% vs 77.7%) but the proportion of working-age adult patients with at least one form of insurance increased significantly, from 66.0% to 71.8% (OR 1.31, CI: 1.13–1.52). The difference-in-differences analysis confirmed the change in insurance coverage among working-age adults was greater than that seen in the reference population of Medicare-eligible adults (AOR 1.70, CI: 1.29–2.23). The increase was almost entirely attributable to increased Medicaid coverage.ConclusionIn the first two years following full implementation of the ACA, there was a significant increase in the proportion of working-age adult ED patients who had at least one form of health insurance. The increase appeared primarily associated with expansion of Medicaid. 相似文献
10.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801